This trial is a Phase II study using the "window-of-opportunity" design in which the
treatment-free window between breast cancer diagnosis and surgical tumor resection is used to
study the biological effects of the beta blocker propranolol .
Phase:
Phase 2
Details
Lead Sponsor:
Texas Tech University Health Sciences Center, El Paso